Idorsia's Fabry Drug Founders In Phase III
Lucerastat Fails To Reduce Neuropathic Pain
The prospects of lucerastat becoming Idorsia's second drug to be filed with regulators, after the insomnia treatment daridorexant, look slim after a Phase III fail for the Fabry disease therapy.
You may also be interested in...
Shares in Protalix sank more than 30% after the company received a complete response letter from US regulators for pegunigalsidase alfa for Fabry disease. No inspection of the company's manufacturing plant in Israel appears to be the main sticking point.
The Swiss major's oncology business performed well in the third quarter with Kisqali sales catching the eye despite the specific problems that the pandemic has brought for breast cancer patients.
CEO Vas Narasimhan sees Novartis very much as an innovative company so the long-awaited strategic review of Sandoz suggests that the generics/biosimilars business could be spun off or sold fairly soon.